Ophthalmic emulsions and suspensions

REFERENCES

• Lang J.C. Ocular Drug Delivery Conventional Ocular Formulations. Adv. Drug Delivery Rev. 1995; 16: 39–43
   Web of Science ®Google Scholar
• Martin A., Swarbrick J., Cammarata A., Chun A.H.C. Physical Pharmacy. 3rd Ed., Lea & Febiger, Philadelphia 1983; 470
   Google Scholar
• Kreuter J. Particulates (Nanoparticles and Microparticles). Ophthalmic Drug Delivery Systems, A.K. Mitra. Marcel Dekker, New York 1993; 275–287
   Google Scholar
• Zimmer A., Kreuter J. Microspheres and Nanoparticles Used in Ocular Delivery Systems. Adv. Drug Delivery Rev. 1995; 16: 61–73, [CROSSREF]
   Web of Science ®Google Scholar
• Joshi A. Microparticulates for Ophthalmic Drug Delivery. J. Ocul. Pharmacol. 1994; 10: 29–45, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Stjernschantz J., Astin M. Anatomy and Physiology of the Eye, Physiological Aspects of Ocular Drug Therapy. Biopharmaceutics of Ocular Drug Delivery, P. Edman. CRC Press, Boca Raton 1993; 1–25
   Google Scholar
• Lee V.H.L. Precorneal, Corneal and Postcorneal Factors. Ophthalmic Drug Delivery Systems, A.K. Mitra. Marcel Dekker, New York 1993; 59–81
   Google Scholar
• Schoenwald R.D. Ocular Pharmacokinetics/Pharmacodynamics. Ophthalmic Drug Delivery Systems, A.K. Mitra. Marcel Dekker, New York 1993; 83–110
   Google Scholar
• Järvinen K., Järvinen T., Urtti A. Ocular Absorption Following Topical Delivery. Adv. Drug Delivery Rev. 1995; 16: 3–19, [CROSSREF]
   Web of Science ®Google Scholar
• Van Ooteghem M. Formulation of Ophthalmic Solutions and Suspensions: Problems and Advantages. Biopharmaceutics of Ocular Drug Delivery, P. Edman. CRC Press, Boca Raton 1993; 27–42
   Google Scholar
• Sieg J.W., Robinson J.R. Vehicle Effects on Ocular Drug Bioavailability. II: Evaluation of Pilocarpine. J. Pharm. Sci. 1977; 66: 1222–1228, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sieg J.W., Robinson J.R. Vehicle Effects on Ocular Drug Bioavailability. III: Shear-Facilitated Pilocarpine Release from Ointments. J. Pharm. Sci. 1979; 68: 724–728, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Puglisi G., Spampinato S., Giammona G., Pignatello R., Bachetti T., Mangiafico S., Marino A., Mazzone G. Effect of Different Ointment Bases on Ocular Anti-inflammatory Activity of 4-Biphenylacetic Acid in the Rabbit. Drug Des. Delivery 1989; 5: 341–352
   Google Scholar
• Martin A., Swarbrick J., Cammarata A., Chun A.H.C. Physical Pharmacy. 3rd Ed., Lea & Febiger, Philadelphia 1983; 565
   Google Scholar
• De Luca M., Vaution C., Rabarron A., Seiller M. Classification et Obtention des Émulsions Multiples. STP Pharma 1988; 4: 679–687
   Google Scholar
• Safwat S.M., Kassem M.A., Attia M.A., El-Mahdy M. The Formulation-Performance Relationship of Multiple Emulsions and Ocular Activity. J. Control. Release 1994; 32: 259–268, [CROSSREF]
   Web of Science ®Google Scholar
• Kassem M.A., Safwat S.M., Attia M.A., El-Mahdy M. Influence of the Phase Volume Ratio of Multiple Emulsions on the Ocular Activity of Prednisolone. STP Pharma 1995; 5: 309–315
   Web of Science ®Google Scholar
• Kassem M.A., Attia M.A., Safwat S.M., El-Mahdy M. Preparation and Evaluation of Hydrocortisone Multiple Emulsions in Rabbit's Eye. Pharm. Ind. 1994; 56: 584–588
   Web of Science ®Google Scholar
• Gasco M.R. Microemulsions in the Pharmaceutical Field: Perspectives and Applications. Industrial Applications of Microemulsions, C. Solans, H. Kunieda. Marcel Dekker, New York 1997; 97–122
   Google Scholar
• Von Dardel O., Mebius C., Mossberg T., Svensson B. Fat Emulsions as a Vehicle for Diazepam. A Study of 9492 Patients. Br. J. Anaesth. 1983; 55: 41–47, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Benita S., Friedman D., Weinstock M. Physostigmine Emulsion: A New Injectable Controlled Release Delivery System. Int. J. Pharm. 1986; 30: 47–55, [CROSSREF]
   Web of Science ®Google Scholar
• Levy M.Y., Benita S. Design and Characterisation of a Submicronized O/W Emulsion of Diazepam for Parenteral Use. Int. J. Pharm. 1989; 54: 103–112, [CROSSREF]
   Web of Science ®Google Scholar
• Benita S., Levy M.Y. Submicron Emulsions as Colloidal Drug Carriers for Intravenous Administration: Comprehensive Physicochemical Characterization. J. Pharm. Sci. 1993; 82: 1069–1079, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Attwood D. Microemulsions. Colloidal Drug Delivery Systems, J. Kreuter. Marcel Dekker, New York 1994; 31–71
   Google Scholar
• Gasco M.R., Gallarate M., Pattarino F. On the Release of Prednisone from Oil in Water Microemulsions. Pr. Ed. (II Farmaco Ed.) 1988; 10: 325–330
   Google Scholar
• Gallarate M., Gasco M.R., Trotta M. Influence of Octanoic Acid on Membrane Permeability of Timolol from Solutions and from Microemulsions. Acta Pharm. Technol. 1988; 34: 102–105
   Web of Science ®Google Scholar
• Gasco M.R., Gallarate M., Trotta M., Bauchiero L., Gremmo E., Chiappero O. Microemulsions as Topical Delivery Vehicles: Ocular Administration of Timolol. J. Pharm. Biomed. Anal. 1989; 7: 433–439, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Trotta M., Gasco M.R., Morel S. Release of Drugs from Oil-Water Microemulsions. J. Control. Release 1989; 10: 237–243, [CROSSREF]
   Web of Science ®Google Scholar
• Gallarate M., Gasco M.R., Trotta M., Chetoni P., Saettone M.F. Preparation and Evaluation In Vitro of Solutions and O/W Microemulsions Containing Levobunolol as Ion Pair. Int. J. Pharm. 1993; 100: 219–225, [CROSSREF]
   Web of Science ®Google Scholar
• Muchtar S., Almog S., Torracca M.T., Saettone M.F., Benita S. A Submicron Emulsion as Ocular Vehicle for Delta-8-tetrahydrocannabinol: Effect on Intraocular Pressure in Rabbits. Ophthalmic Res. 1992; 24: 142–149, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Muchtar S., Abdulrazik M., Frucht-Pery J., Benita S. Ex-Vivo Permeation Study of Indomethacin from a Submicron Emulsion Through Albino Rabbit Cornea. J. Control. Release 1997; 44: 55–64, [CROSSREF]
   Web of Science ®Google Scholar
• Calvo P., Alonso M.J., Vila-Jato J., Robinson J.R. Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers. J. Pharm. Pharmacol. 1996; 48: 1147–1152, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Yu W., Tabosa do Egito E.S., Barratt G., Fessi H., Devissaguet J.P., Puisieux F. A Novel Approach to the Preparation of Injectable Emulsions by a Spontaneous Emulsification Process. Int. J. Pharm. 1993; 89: 139–146, [CROSSREF]
   Web of Science ®Google Scholar
• Naveh N., Muchtar S., Benita S. Pilocarpine Incorporated into a Submicron Emulsion Vehicle Causes an Unexpectedly Prolonged Ocular Hypotensive Effect in Rabbits. J. Ocul. Pharmacol. 1994; 10: 509–520, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Muchtar S., Benita S. Emulsions as Drug Carriers for Ophthalmic Use. Colloids Surf. 1994; 91: 181–190, [CROSSREF]
   Google Scholar
• Klang S.H., Frucht-Pery J., Hoffman A., Benita S. Physicochemical Characterization and Acute Toxicity Evaluation of a Positively Charged Submicron Emulsion Vehicle. J. Pharm. Pharmacol. 1994; 46: 986–993, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Klang S.H., Baszkin A., Benita S. The Stability of Piroxicam Incorporated in a Positively Charged Submicron Emulsion for Ocular Administration. Int. J. Pharm. 1996; 132: 33–44, [CROSSREF]
   Web of Science ®Google Scholar
• Wehrle P., Korner D., Benita S. Sequential Statistical Optimisation of a Positively-Charged Submicron Emulsion of Miconazole. Pharm. Dev. Technol. 1996; 1: 97–111, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Cohen T., Sauvageon-Martre H., Brossard D., D'Hermies F., Bardin C., Chast F., Chaumeil J.C. Amphotericin B Eye Drops as a Lipidic Emulsion. Int. J. Pharm. 1996; 127: 249–254, [CROSSREF]
   Google Scholar
• Siebenbrodt I., Keipert S. Versuche Zur Entwicklung und Charakterisierung Ophthalmologisch Verwendbarer Tensidhaltiger Mehrkomponentensysteme. Pharmazie 1991; 46: 435–438
   Google Scholar
• Siebenbrodt I., Keipert S. Poloxamer-Systeme als Potentielle Ophthalmika. Teil 1: Viskose Polymertensidlosungen. Chem Abstr. 1992; 117: 135–141, 178192m
   Google Scholar
• Siebenbrodt I., Keipert S. Poloxamer-Systems as Potential Ophthalmics. II: Microemulsions. Eur. J. Pharm. Biopharm. 1993; 39: 25–30
   Web of Science ®Google Scholar
• Skinner F.S. Suspensions-Augentrofen. Ophthalmika: Pharmakologie, Biopharmazie und Galenik der Augenarzneimittel, R. Dolder, F.S. Skinner. 4th Ed., WV GmbH, Stuttgart 1990; 441–447
   Google Scholar
• Skinner F.S. Die Teilchenfeinheit in Augensalben. Ophthalmika: Pharmakologie, Biopharmazie und Galenik der Augenarzneimittel, R. Dolder, F.S. Skinner. 4th Ed., WV GmbH, Stuttgart 1990; 469–483
   Google Scholar
• Sieg J.W., Robinson J.R. Vehicle Effects on Ocular Drug Bioavailability I: Evaluation of Fluorometholone. J. Pharm. Sci. 1975; 64: 931–936, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Schoenwald R.D., Boltralik J.J. A Bioavailability Comparison in Rabbits of Two Steroids Formulated as High Viscosity Gels and Reference Aqueous Preparations. Investig. Ophthalmol. Vis. Sci. 1979; 18: 61–66
   PubMed Web of Science ®Google Scholar
• Kupferman A., Ryan W.J., Leibowitz H.M. Prolongation of Anti-inflammatory Effect of Prednisolone Acetate. Arch. Ophthalmol. 1981; 99: 2028–2029, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Burgalassi S., Chetoni P., Saettone M.F. Hydrogels for Ocular Delivery of Pilocarpine: Preliminary Evaluation in Rabbits of the Influence of Viscosity and of Drug Solubility. Eur. J. Pharm. Biopharm. 1996; 42: 385–392
   Web of Science ®Google Scholar
• Johansen S., Rask-Pedersen E., Prause J.U. A Bioavailability Comparison in Rabbits After a Single Topical Ocular Application of Prednisolone Acetate Formulated as High-Viscosity Gel and as an Aqueous Suspension. Acta Ophthalmol. Scand. 1996; 74: 253–258, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Slovin E.M., Robinson J.R. Bioadhesives in Ocular Drug Delivery. Biopharmaceutics of Ocular Drug Delivery, P. Edman. CRC Press, Boca Raton 1993; 145–157
   Google Scholar
• Higuchi T. Rate of Release of Medicaments Form Ointment Bases Containing Drugs in Suspension. J. Pharm. Sci. 1961; 50: 874–875, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lippmann O. Local Irritating Effect Caused by Topical Use of Steroids in the Eye. AMA Arch. Ophthalmol. 1957; 57: 339–344, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Schoenwald R.D., Stewart P. Effect of Particle Size on Ophthalmic Bioavailability of Dexamethasone Suspensions in Rabbits. J. Pharm. Sci. 1980; 69: 391–394, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sieg J.W., Triplett J.W. Precorneal Retention of Topically Instilled Micronized Particles. J. Pharm. Sci. 1980; 69: 863–864, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hui H.-W., Robinson J.R. Effect of Particle Dissolution Rate on Ocular Drug Bioavailability. J. Pharm. Sci. 1986; 75: 280–287, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bisrat M., Nyström C., Edman P. Influence of Dissolution Rate of Sparingly Soluble Drugs on Corneal Permeability In Vitro. Int. J. Pharm. 1990; 63: 49–56, [CROSSREF]
   Google Scholar
• Howard S.A., Mauger J.W., Phusanti L. Dissolution Profiles for Multisized Prednisolone Acetate Suspensions. J. Pharm. Sci. 1977; 66: 557–559, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Howard S.A., Mauger J.W., Hsieh J.W., Amin K. Suspending Agent Effects on Steroid Suspension Dissolution Profiles. J. Pharm. Sci. 1979; 68: 1475–1479, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Patel N.K., Kennon L., Levinson R.S. Pharmaceutical Suspensions. The Theory and Practice of Industrial Pharmacy, L. Lachman, H.A. Lieberman, J.L. Kanig. 3rd Ed., Lea & Febiger, Philadelphia 1986; 479–501
   Google Scholar
• Bartlett J.D. Ophthalmic Drug Delivery. Clinical Ocular Pharmacology, J.D. Bartlett, S.D. Jaanus. 3rd Ed., Lea & Febiger, Philadelphia 1995; 47–74
   Google Scholar
• Norell S.E., Granström P.A. Self-medication with Pilocarpine Among Outpatients in a Glaucoma Clinic. Br. J. Ophthalmol. 1980; 64: 137–141, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kass M.A., Hodapp E., Gordon M., Kolker A.E., Goldberg I. Patient Administration of Eyedrops: Observation, Part II. Ann. Ophthalmol. 1982; 14: 889–893, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Apt L., Henrick A., Silverman L.M. Patient Compliance with Use of Topical Ophthalmic Corticosteroid Suspensions. Am. J. Ophthalmol. 1979; 87: 210–214, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• MacKeen D.L. Aqueous Formulations and Ointments. Int. Ophthalmol. Clin. 1980; 20: 79–92, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Kwon K.A., Diestelhorst M., Säuverkräup R. Dosage Problems in Suspension Eyedrops. Klin. Monatsbl. Augenheilkd. 1996; 209: 144–149, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jani R., Gan O., Ali Y., Rodstrom R., Hancock S. Ion Exchange Resins for Ophthalmic Delivery. J. Ocul. Pharmacol. 1994; 10: 57–67, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Bean H.S., Dempsey G. The Effect of Suspensions on the Bactericidal Activity of m-Cresol and Benzalkonium Chloride. J. Pharm. Pharmacol. 1971; 23: 609–704
   Google Scholar
• Vulovic N., Primorac M., Stupar M., Brown M.W., Ford J.L. Some Studies on the Preservation of Indomethacin Suspensions Intended for Ophthalmic Use. Pharmazie 1990; 45: 678–679, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Camber O., Edman P. Influence of Some Preservatives on the Corneal Permeability of Pilocarpine and Dexamethasone, In Vitro. Int. J. Pharm. 1987; 39: 229–234, [CROSSREF]
   Web of Science ®Google Scholar
• Frederick K.J. Performance and Problems of Pharmaceutical Suspensions. J. Pharm. Sci. 1961; 50: 531–535, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hecht G. Ophthalmic Preparations. Remington: The Science and Practice of Pharmacy, A.R. Gennaro. 19th Ed., Mack Publ. Co., Easton, PA 1995; 1563–1568
   Google Scholar
• Kuhnert-Brandstätter M. Polymorphe and Pseudopolymorphe Kristallformen von Steroidhormonen. Pharm. Ind. 1977; 39: 377–383
   Google Scholar
• Carless J.E., Moustafa M.A., Rapson D.C. Dissolution and Crystal Growth in Aqueous Suspensions of Cortisone Acetate. J. Pharm. Pharmacol. 1968; 20: 630–638, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Varney G. Crystal Growth in Aqueous Suspensions. J. Pharm. Pharmacol. 1967; 19: 19S–23S, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• List P.H., Grönig J.M. Teilchengrössenbestimmung in Augensalben. Pharm. Ind. 1976; 38: 1159–1171
   Google Scholar
• Collard R.E. Formulation and Manufacture of Corticosteroid Preparations. Pharm. J. 1961; 186: 113–117
   Google Scholar
• Techniques of Solubilization of Drugs, S.H. Yalkowsky. Marcel Dekker, New York 1981
   Google Scholar
• Pharmaceutical Emulsions and Suspensions, J.-L. Salager. Marcel Dekker, New York 2000
   Google Scholar